The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial of α-particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML.
 
Joseph G. Jurcic
Consulting or Advisory Role - Amgen; Bayer; Novartis; Sunesis Pharmaceuticals
Research Funding - Actinium Pharmaceuticals; Ambit BioSciences; Astellas Pharma; Celgene
Travel, Accommodations, Expenses - Celgene; Sunesis Pharmaceuticals
 
Farhad Ravandi
Research Funding - Actinium Pharmaceuticals
 
John M. Pagel
No Relationships to Disclose
 
Jae Hong Park
Consulting or Advisory Role - Amgen
Research Funding - Genentech; Juno Therapeutics
 
B. Douglas Smith
No Relationships to Disclose
 
Dan Douer
Honoraria - Sigma-Tau; Spectrum Pharmaceuticals
Consulting or Advisory Role - Gilead Sciences; Jazz Pharmaceuticals; Sigma-Tau; Spectrum Pharmaceuticals
Research Funding - Amgen; Bristol-Myers Squibb; Sigma-Tau
 
Moshe Yair Levy
Research Funding - Actinium Pharmaceuticals
 
Elihu Estey
No Relationships to Disclose
 
Hagop M. Kantarjian
Research Funding - Amgen (Inst); ARIAD (Inst); Bristol-Myers Squibb (Inst); Delta-Fly Pharma (Inst); Novartis (Inst); Pfizer (Inst)
 
Dennis Earle
Employment - Actinium Pharmaceuticals
Stock and Other Ownership Interests - Actinium Pharmaceuticals
 
Dragan Cicic
Employment - Actinium Pharmaceuticals
Stock and Other Ownership Interests - Actinium Pharmaceuticals
 
David A. Scheinberg
Stock and Other Ownership Interests - Actinium Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Actinium Pharmaceuticals; Novartis